New combo therapy targets Hard-to-Treat lung cancer in veterans

NCT ID NCT05467748

Recruiting now Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs—tulmimetostat (an EZH2 inhibitor) and pembrolizumab (an immunotherapy)—in 66 veterans with advanced non-small cell lung cancer that has worsened after initial treatment. The goal is to see if the combination can shrink tumors or slow cancer growth. Participants will receive the drugs intravenously and be monitored for side effects and response. This is not a cure; the aim is to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Michael E. DeBakey VA Medical Center, Houston, TX
RECRUITING

Houston, Texas, 77030-4211, United States
VA Ann Arbor Healthcare System, Ann Arbor, MI
RECRUITING

Ann Arbor, Michigan, 48105-2303, United States
VA Long Beach Healthcare System, Long Beach, CA
NOT_YET_RECRUITING

Long Beach, California, 90822, United States
VA Northern California Health Care System, Mather, CA
NOT_YET_RECRUITING

Sacramento, California, 95655-4200, United States
VA San Diego Healthcare System, San Diego, CA
RECRUITING

San Diego, California, 92161-0002, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.